Physician profile
Steven James Shook
NPI 1043862733
$5,271.07
in general payments reported to CMS, 2019-2025
22 companies · $3,565 in 2025
The $3,565 reported for 2025 was more than what 98% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $961 · 2024: $746 · 2025: $3,565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,195 · Travel and Lodging: $2,076.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,195.03 |
| Travel and Lodging | $2,076.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $3,084.06 | 2023-2025 | Inspire |
| Astrazeneca Pharmaceuticals LP | $306.70 | 2023-2025 | Tezspire, Airsupra |
| Insmed, INC. | $283.24 | 2023-2025 | Arikayce |
| Mylan Specialty L.P. | $254.94 | 2023-2024 | Yupelri, Yupelri |
| Regeneron Healthcare Solutions, INC. | $171.09 | 2024-2025 | Dupixent |
| Ceribell, INC. | $162.95 | 2024 | Pocket Eeg Device |
| Takeda Pharmaceuticals U.S.A., INC. | $147.01 | 2023-2025 | Glassia |
| Abiomed | $146.14 | 2023 | Impella |
| Glaxosmithkline, LLC. | $120.74 | 2024-2025 | Nucala, Trelegy Ellipta |
| Genzyme Corporation | $111.11 | 2024-2025 | |
| Baxter Healthcare | $104.89 | 2023 | Hillrom - Life 2000 Ventilation System |
| Viatris Specialty LLC | $60.30 | 2025 | Yupelri |
| Jazz Pharmaceuticals INC. | $52.97 | 2024-2025 | |
| Verona Pharma, INC. | $52.06 | 2025 | Ohtuvayre |
| Amgen INC. | $36.88 | 2025 | Tezspire |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $36.13 | 2023-2024 | Wakix |
| Electromed, INC. | $33.21 | 2025 | Smartvest |
| Paratek Pharmaceuticals, INC. | $24.98 | 2025 | Nuzyra |
| Novartis Pharmaceuticals Corporation | $22.98 | 2023 | |
| United Therapeutics Corporation | $22.78 | 2025 | Tyvaso |
| Lilly USA, LLC | $18.41 | 2025 | Zepbound |
| Ani Pharmaceuticals, INC. | $17.50 | 2025 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Shook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.